Olema Pharmaceuticals, Inc. Common Stock
OLMA Real Time Price USDRecent trades of OLMA by members of U.S. Congress
|
Name
|
Type
|
Shares
|
Price
|
Shares Held
|
Date
|
Reported
|
|---|
|
Investor
|
Shares
|
Change in Shares
|
Market Value
|
Date
|
Reported
|
|---|
|
Investor
|
Type
|
Shares
|
Change in Shares
|
Market Value
|
Date
|
Reported
|
|---|
Recently reported changes by institutional investors
Quarterly net insider trading by OLMA's directors and management
Government lobbying spending instances
Estimated quarterly lobbying spending
New patents grants
-
Patent Title: Tetrahydro-1h-pyrido [3,4-b]indole anti-estrogenic drugs Jun. 13, 2023
-
Patent Title: Tetrahydro-1h-pyrido [3,4-b]indole anti-estrogenic drugs Jan. 25, 2022
-
Patent Title: Tetrahydro-1h-pyrido[3,4-b]indole anti-estrogenic drugs May. 21, 2019
-
Patent Title: Benzopyran compounds, compositions and uses thereof Apr. 28, 2015
-
Patent Title: Substituted triphenyl butenes Nov. 22, 2011
Federal grants, loans, and purchases
Estimated quarterly amount awarded from public contracts
Number of mentions of OLMA in WallStreetBets Daily Discussion
Recent insights relating to OLMA
Recent picks made for OLMA stock on CNBC
ETFs with the largest estimated holdings in OLMA
The Quiver Smart Score combines our data on Congress Trading, Lobbying, Insider Trading, CNBC Mentions and more to provide a comprehensive view of the strength of a stock's underlying data.
The Smart Score grades stocks on a scale of 1 (weakest) to 10 (strongest) based on the strength of the underlying data.Sign Up to view OLMA Smart Score
See concise summaries of analyst reports, presenting both bullish and bearish arguments for a stock.
Example:
The Bulls Say summary highlights positive aspects of the stock.
The Bears Say summary points out potential risks and negative aspects of the stock.